drugset
drugset / Trial / NCT03245229

A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-132577 Can Affect Rosuvastatin's Fate in the Body (Amount and Time of Presence in the Blood)

NCT03245229 ↗

Phase 1 Completed 20 enrolled Idorsia Pharmaceuticals Ltd.
Non-randomizedSingle-groupOpen-labelOther

Summary

The primary purpose of this study is to investigate the effect of Aprocitentan (ACT-132577) at steady state on the pharmacokinetics of single-dose rosuvastatin in healthy male subjects

Timeline

Start
2017-08-10
Primary completion
2017-09-18
Completion
2017-09-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Aprocitentan Small molecule 25 mg Oral
Subject Rosuvastatin Small molecule 10 mg Oral

Indications

No indication recorded.